

## S 1423

### Preserving Access to Orphan Drugs Act of 2011

**Congress:** 112 (2011–2013, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Jul 27, 2011

**Current Status:** Read twice and referred to the Committee on Finance.

**Latest Action:** Read twice and referred to the Committee on Finance. (Jul 27, 2011)

**Official Text:** <https://www.congress.gov/bill/112th-congress/senate-bill/1423>

## Sponsor

**Name:** Sen. Toomey, Patrick [R-PA]

**Party:** Republican • **State:** PA • **Chamber:** Senate

## Cosponsors (5 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Casey, Robert P., Jr. [D-PA]	D · PA		Jul 27, 2011
Sen. Wyden, Ron [D-OR]	D · OR		Jul 27, 2011
Sen. Carper, Thomas R. [D-DE]	D · DE		Sep 20, 2012
Sen. Crapo, Mike [R-ID]	R · ID		Nov 13, 2012
Sen. Wicker, Roger F. [R-MS]	R · MS		Dec 4, 2012

## Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Jul 27, 2011

## Subjects & Policy Tags

### Policy Area:

Health

## Related Bills

Bill	Relationship	Last Action
112 HR 2672	Identical bill	Aug 1, 2011: Referred to the Subcommittee on Health.

## Summary (as of Jul 27, 2011)

Preserving Access to Orphan Drugs Act of 2011 - Amends the Patient Protection and Affordable Care Act (PPACA) to exclude any drug or biological product which is approved or licensed by the Food and Drug Administration (FDA) for marketing solely for one or more rare diseases or conditions from the annual fee on manufacturers or importers with branded prescription drug sales exceeding \$5 million.

Makes this Act effective as if included in PPACA.

## **Actions Timeline**

---

- **Jul 27, 2011:** Introduced in Senate
- **Jul 27, 2011:** Read twice and referred to the Committee on Finance.